Frontiers in Immunology (Sep 2023)

Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood

  • Claudia Günther,
  • Christine Wolf,
  • Louisa Fennen,
  • Sarah Rösing,
  • Stefan Beissert,
  • Martin Aringer,
  • Min Ae Lee-Kirsch

DOI
https://doi.org/10.3389/fimmu.2023.1253279
Journal volume & issue
Vol. 14

Abstract

Read online

Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained remission of previously refractory CLE lesions, beginning within the first weeks of treatment. Decline in CLASI-A score was paralleled by a reduction in IFN score determined by mRNA expression of seven IFN-stimulated genes (ISGs) in blood. These data suggest that a subset of ISGs could be a valuable biomarker in CLE.

Keywords